Atrial Fibrillation- Pipeline Insight, 2024

Atrial Fibrillation- Pipeline Insight, 2024

DelveInsight’s, “Atrial Fibrillation- Pipeline Insight, 2024” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Atrial Fibrillation pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Atrial Fibrillation: Understanding

Atrial Fibrillation: Overview

Atrial fibrillation (also called Afib or AF) is an irregular heart rhythm (arrhythmia) that begins in the upper (atria) of your heart. In atrial fibrillation, the normal cycle of electrical impulses in the heart is interrupted. This leads to a fast, chaotic heart rhythm and poor movement of blood from your atria to lower chambers (ventricles). There are three main types of atrial fibrillation.

• Paroxysmal Afib lasts less than one week and usually stops on its own without treatment.
• Persistent Afib lasts more than one week and needs treatment.
• Long-standing persistent Afib lasts more than a year and is sometimes difficult to treat.

Some people with Afib have no symptoms. It depends on how fast ventricles are beating. If they’re beating at a normal or slightly elevated pace, probably it won’t feel anything. But if ventricles beat faster than symptoms are noticed. These can include extreme fatigue, an irregular heartbeat, heart palpitations, a feeling of butterflies or a fish flopping in your chest, dizziness or lightheadedness, fainting (syncope), shortness of breath (dyspnea), chest pain (angina).

The diagnosis of Afib includes physical examination and lab tests. Physical examination includes listening to your heart rhythm with a stethoscope, checking your pulse and blood pressure, checking the size of your thyroid gland to identify thyroid problems, looking for swelling in your feet or legs to identify heart failure, listening to your lungs to detect heart failure or infection and the tests include the following:

• Electrocardiogram (EKG or ECG): An EKG is usually the first test. It’s painless and takes about three minutes. It measures and records your heart’s electrical signals and allows your provider to see if your heart is beating normally.
• Echocardiogram (echo): An echo uses ultrasound technology to show heart movement. It can reveal problems with blood flow and heart muscle contractions.
• Blood tests: Sometimes, imbalances in our blood can cause Afib. Simple blood tests can show potassium and thyroid hormone levels and can help provider choose the best medicines based on your liver and kidney function.

Based on symptoms and severity the doctor may suggest medications or surgical procedures as treatment of Afib. Medications to treat Afib may include:

 Rate control medications to prevent the ventricles from beating too fast. Examples include digoxin, metoprolol, verapamil or diltiazem.

 Rhythm control medications to help your heart beat in a normal sinus rhythm. Examples include procainamide, disopyramide, flecainide acetate, propafenone, sotalol, dofetilide or amiodarone.

 Blood thinners (anticoagulant medications) to reduce the risk of blood clots and stroke. Examples include warfarin, warfarin alternatives or aspirin.

If medications don’t help your Afib, procedure or surgery is needed:

 Electrical cardioversion electrically “resets” heart rhythm using low-energy shocks, but it may only be a temporary solution.

 Pulmonary vein ablation uses catheters to deliver energy outside and around pulmonary veins. This procedure helps respond better to your Afib medications.

 A permanent pacemaker may be inserted in case of slow heart rate. Usually, it’s only used if the patient have another arrhythmia in addition to Afib.

 Left atrial appendage closure is a procedure that reduces your risk of blood clots and stroke.

 The MAZE procedure creates scar tissue that helps heart’s electrical impulses travel in the right path. This procedure has a high success rate. If the patient have severe Afib symptoms and a history of stroke or blood clots, provider may recommend this option.

""Atrial Fibrillation- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Atrial Fibrillation pipeline landscape is provided which includes the disease overview and Atrial Fibrillation treatment guidelines. The assessment part of the report embraces, in depth Atrial Fibrillation commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Atrial Fibrillation collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Atrial Fibrillation R&D. The therapies under development are focused on novel approaches to treat/improve Atrial Fibrillation.

Atrial Fibrillation Emerging Drugs Chapters

This segment of the Atrial Fibrillation report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Atrial Fibrillation Emerging Drugs

• Abelacimab: Anthos Therapeutics, Inc.

Abelacimab is under development for the prevention of arterial and venous thrombosis, venous thromboembolism (VTE), pulmonary embolism, deep vein thrombosis, inflammation and stroke and systemic embolism in patients with atrial fibrillation. Abelacimab is under Phase III clinical development by Anthos Therapeutics for Atrial fibrillation.

• Etripamil: Milestone Pharmaceuticals

Etripamil is designed to be a rapid-response therapy for episodic cardiovascular conditions. The novel calcium channel blocker is self-administered via a nasal spray, which may shift the current treatment paradigm for many patients with PSVT from the emergency department to the at-home setting. The drug is in Phase III clinical studies for the treatment of paroxysmal supraventricular tachycardia and in Phase II clinical studies to treat atrial fibrillation.

• GENCARO: ARCA biopharma

Gencaro (bucindolol hydrochloride) is a pharmacologically unique beta-blocker and mild vasodilator that we believe has potential for the treatment and prevention of recurrent atrial fibrillation, or AF, in patients with heart failure with mid-range ejection fraction, or HFmrEF. Beta-blockers, a well characterized class of drugs, target cardiac myocytes to reduce adverse beta1- adrenergic signaling that causes cardiac chamber remodeling. Gencaro’s mechanism of action (MOA) is unique among beta-blockers due to its sympatholytic (norepinephrine lowering) and inverse agonism (inactivation of constitutively active receptors) properties. The drug is in Phase II/III clinical studies for the treatment and prevention of recurrent atrial fibrillation, or AF, in patients with heart failure with mid-range ejection fraction, or HFmrEF.

Further product details are provided in the report……..

Atrial Fibrillation: Therapeutic Assessment

This segment of the report provides insights about the different Atrial Fibrillation drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Atrial Fibrillation

There are approx. 15+ key companies which are developing the therapies for Atrial Fibrillation. The companies which have their Atrial Fibrillation drug candidates in the most advanced stage, i.e. phase III include, Anthos Therapeutics, Inc.

• Phases

DelveInsight’s report covers around 15+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Atrial Fibrillation pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Atrial Fibrillation: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Atrial Fibrillation therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Atrial Fibrillation drugs.

Atrial Fibrillation Report Insights

• Atrial Fibrillation Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Atrial Fibrillation Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Atrial Fibrillation drugs?
• How many Atrial Fibrillation drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Atrial Fibrillation?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Atrial Fibrillation therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Atrial Fibrillation and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• ARCA biopharma Inc
• Anthos Therapeutics, Inc.
• Milestone Pharmaceuticals
• Armaron Biosciences
• Ono Pharmaceutical
• Hanmi Pharmaceutical
• HUYA Bioscience International
• Hyloris Pharmaceuticals
• Vivasc Therapeutics
• Espero BioPharma

Key Products

• Gencaro
• Abelacimab
• Etripamil
• OMT 28
• NP 202
• HIP-2001
• Sulcardine
• HY-CVS-033
• CTP-amio
• ESP-001